Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. ImmuPharma plc
  6. Summary
    IMM   GB0033711010

IMMUPHARMA PLC

(IMM)
  Report
Delayed London Stock Exchange  -  11:35:14 2023-01-30 am EST
2.700 GBX   -9.24%
01/19Immunovia Announces Realigning Swedish Operations with Strategic Priorities and Its Focus on the US Commercialization of the IMMray™ PanCan-d test
CI
01/17Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray PanCan-d test in the US market
CI
01/05Immupharma : Major Interest | TR1 | Gary Smith
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusFunds 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/24/2023 01/25/2023 01/26/2023 01/27/2023 01/30/2023 Date
2.715(c) 3.075(c) 3.015(c) 2.975(c) 2.7(c) Last
406 577 4 772 867 615 696 2 206 512 1 077 631 Volume
+4.42% +13.26% -1.95% -1.33% -9.24% Change
More quotes
Estimated financial data (e)
Sales 2020 0,13 M 0,16 M 0,16 M
Net income 2020 -6,86 M -8,49 M -8,49 M
Net cash position 2020 5,22 M 6,46 M 6,46 M
P/E ratio 2020 -3,89x
Yield 2020 -
Sales 2021 0,12 M 0,15 M 0,15 M
Net income 2021 -8,17 M -10,1 M -10,1 M
Net cash position 2021 1,65 M 2,04 M 2,04 M
P/E ratio 2021 -2,03x
Yield 2021 -
Capitalization 9,00 M 11,1 M 11,1 M
EV / Sales 2020 223x
EV / Sales 2021 126x
Nbr of Employees 14
Free-Float 56,2%
More Financials
Company
ImmuPharma PLC is a pharmaceutical development company, which discovers and develops peptide-based therapeutics. It is focused on the development of drugs based on peptide therapeutics, to treat serious medical conditions such as autoimmune disease. Its portfolio consists of four peptide therapy areas, which include autoimmunity and anti-infectives. Its lead program, Lupuzor is a first-in class autophagy... 
Read more
More about the company
All news about IMMUPHARMA PLC
01/19Immunovia Announces Realigning Swedish Operations with Strategic Priorities and Its Foc..
CI
01/17Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs t..
CI
01/05Immupharma : Major Interest | TR1 | Gary Smith
PU
01/04Immupharma : Major Interest | TR1 | Lanstead Capital – 3 January 2023
PU
2022TRADING UPDATES: Ground Rents Income Fund's portfolio value drops
AN
2022Immupharma : Avion confirms its continued support to the Lupuzor™ clinical program i..
PU
2022TRADING UPDATES: Driver records loss; Synectics sells business unit
AN
2022ImmuPharma's US Partner Confirms Support for Lupus Medication's Clinical Program
MT
2022ImmuPharma, Avion Agree to Continue Lupus Program; Explore Distribution Agreement
DJ
2022ImmuPharma plc Appoints Ward Williams Limited as Company Secretary
CI
2022Earnings Flash (IMM.L) IMMUPHARMA Reports H1 Loss GBX-0.58
MT
2022ImmuPharma plc Reports Earnings Results for the Half Year Ended June 30, 2022
CI
2022Immupharma Falls 21% as US Partner Receives Further US FDA Direction for Lupus Medicati..
MT
2022ImmuPharma Shares Fall on FDA's Lupuzor Treatment Response
DJ
2022ImmuPharma Says US Partner Hasn't Had Written Response From FDA Over Lupuzor
DJ
More news
News in other languages on IMMUPHARMA PLC
01/19Immunovia annonce le réalignement de ses opérations suédoises sur ses priorités stratég..
01/17Immunovia nomme Lara E. Sucheston-Campbell au poste de chef des affaires cliniques et m..
2022MISES À JOUR COMMERCIALES : La valeur du portefeuille du Groun..
2022Le partenaire américain d'ImmuPharma confirme son soutien au programme clinique du médi..
2022ImmuPharma plc nomme Ward Williams Limited comme secrétaire de la société
More news
Chart IMMUPHARMA PLC
Duration : Period :
ImmuPharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUPHARMA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 2,70 GBX
Average target price 2,90 GBX
Spread / Average Target 7,41%
Managers and Directors
Timothy Paul McCarthy Chairman & Chief Executive Officer
Ewa Flynn Chief Financial Officer
Timothy Gary Franklin Chief Operating Officer & Director
Sanjeev Pandya Senior Independent Non-Executive Director
Lisa Baderoon Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUPHARMA PLC46.74%11
MODERNA, INC.5.42%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.64%28 465
SEAGEN INC.8.93%26 117